Accelerating Drug Development: Altasciences and Evidence Matters Showcase AI-Driven Efficiencies in Clinical Reporting
Altasciences and Evidence Matters have successfully demonstrated the effectiveness of their RegulatoryFlow (RegFlow) platform, showcasing the integration of AI-driven efficiencies in clinical reporting into nonclinical workflows. This collaboration, which began in August 2025, has shown promising results in accelerating drug development timelines by applying AI capabilities to nonclinical data parsing. The Altasciences Acceleration Platform aims to expedite drug development across the early-phase development continuum, with a focus on enhancing data mapping and usability in clinical reporting.
The proof-of-concept (POC) conducted by Altasciences and Evidence Matters revealed significant advancements in accurately parsing datasets and streamlining nonclinical reporting workflows. This innovative approach represents a groundbreaking AI bridge between nonclinical and clinical phases, enabling more efficient development pathways and allowing internal resources to concentrate on higher-value scientific work. The collaboration continues to evolve with recent platform enhancements and software releases to further enhance performance in clinical reporting.
Altasciences is a fully integrated drug development organization that offers pharmaceutical and biotechnology companies a flexible and proven approach to conducting preclinical and clinical studies. With over 30 years of experience, Altasciences provides a range of services, including bioanalysis, program management, clinical pharmacology, and medical writing, tailored to meet the specific needs of sponsors. Evidence Matters, on the other hand, is a leader in clinical trials data science, leveraging AI solutions to streamline regulatory writing and transform complex data into actionable insights for life sciences teams worldwide. With a team of experienced data scientists and industry leaders, Evidence Matters drives innovation and shapes the future of data-driven decision-making.
In conclusion, the successful proof-of-concept of RegulatoryFlow by Altasciences and Evidence Matters marks a significant milestone in accelerating drug development timelines through the integration of AI-driven efficiencies in nonclinical workflows. This collaboration showcases the potential of AI capabilities to enhance data parsing, streamline reporting workflows, and bridge the gap between nonclinical and clinical phases, ultimately paving the way for more efficient drug development pathways.